OTCPK:IPDQ.F

Stock Analysis Report

Executive Summary

ImpediMed Limited, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy devices and software services in Australia, North America, and internationally.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Risks

  • ImpediMed has significant price volatility in the past 3 months.

Share Price & News

How has ImpediMed's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-15.7%

IPDQ.F

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

-66.3%

IPDQ.F

9.9%

US Medical Equipment

0.6%

US Market

IPDQ.F underperformed the Medical Equipment industry which returned 9.5% over the past year.

IPDQ.F underperformed the Market in United States of America which returned 1.1% over the past year.


Share holder returns

IPDQ.FIndustryMarket
7 Day-15.7%1.1%-0.6%
30 Day19.5%0.6%2.2%
90 Day55.1%2.9%1.1%
1 Year-66.3%-66.3%10.8%9.9%2.9%0.6%
3 Year-89.4%-89.4%70.1%64.9%44.6%35.2%
5 Year-71.3%-71.3%138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is ImpediMed's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ImpediMed undervalued based on future cash flows and its price relative to the stock market?

4.21x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for ImpediMed to establish if it is available at moderate discount.

Unable to calculate intrinsic value for ImpediMed to establish if it is available at substantial discount.


Price Based on Earnings

ImpediMed is loss making, we can't compare its value to the US Medical Equipment industry average.

ImpediMed is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for ImpediMed, we can't assess if its growth is good value.


Price Based on Value of Assets

ImpediMed is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is ImpediMed expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

53.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

ImpediMed's revenue is expected to grow significantly at over 20% yearly.

ImpediMed is not considered high growth as it is expected to be loss making for the next 1-3 years.

ImpediMed's revenue growth is expected to exceed the United States of America market average.

Unable to compare ImpediMed's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare ImpediMed's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if ImpediMed will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has ImpediMed performed over the past 5 years?

-17.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

ImpediMed does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare ImpediMed's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare ImpediMed's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if ImpediMed has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if ImpediMed has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if ImpediMed improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is ImpediMed's financial position?


Financial Position Analysis

ImpediMed is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

ImpediMed's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

ImpediMed has no debt.

ImpediMed has not taken on any debt in the past 5 years.


Balance Sheet

Low level of unsold assets.

ImpediMed has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

ImpediMed has less than a year of cash runway based on current free cash flow.

ImpediMed has less than a year of cash runway if free cash flow continues to reduce at historical rates of -1.8% each year.


Next Steps

Dividend

What is ImpediMed's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate ImpediMed's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate ImpediMed's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as ImpediMed has not reported any payouts.

Unable to verify if ImpediMed's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as ImpediMed has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of ImpediMed's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of ImpediMed's salary, the management and board of directors tenure and is there insider trading?

4.7yrs

Average management tenure


CEO

Rick Carreon 0

7.2yrs

Tenure

AU$2,497,973

Compensation

Mr. Richard Carreon, also known as Rick, has been the Managing Director of ImpediMed Limited since May 9, 2015 and as its Chief Executive Officer and President since July 10, 2012. Mr. Carreon is a seasone ...


CEO Compensation Analysis

Rick's remuneration is higher than average for companies of similar size in United States of America.

Rick's compensation has increased whilst company is loss making.


Management Age and Tenure

4.7yrs

Average Tenure

The tenure for the ImpediMed management team is about average.


Board Age and Tenure

2.5yrs

Average Tenure

60yo

Average Age

The average tenure for the ImpediMed board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by ImpediMed individual insiders in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

SellAU$112,48016 Sep 19
Macquarie Investment Management Limited
EntityCompany
Shares964,882
Max PriceAU$0.12
BuyAU$4,55016 Sep 19
Macquarie Investment Management Limited
EntityCompany
Shares47,393
Max PriceAU$0.096
BuyAU$266,84310 Sep 19
UniSuper Limited
EntityCompany
Shares2,780,630
Max PriceAU$0.096
SellAU$529,37430 Aug 19
Orbis Investment Management Limited
EntityCompany
Shares5,627,285
Max PriceAU$0.098
BuyAU$220,34520 Aug 19
Macquarie Investment Management Limited
EntityCompany
Shares2,167,321
Max PriceAU$0.10
SellAU$114,51720 Aug 19
Macquarie Investment Management Limited
EntityCompany
Shares1,206,843
Max PriceAU$0.095
SellAU$548,79702 Aug 19
Orbis Investment Management Limited
EntityCompany
Shares974,400
Max PriceAU$0.78
BuyAU$2,142,53102 Aug 19
Orbis Investment Management Limited
EntityCompany
Shares17,999,081
Max PriceAU$0.35
SellAU$2,87630 Jul 19
Macquarie Investment Management Limited
EntityCompany
Shares29,539
Max PriceAU$0.097
SellAU$029 Jul 19
Macquarie Investment Management Limited
EntityCompany
Shares394,021
Max PriceAU$0.11
BuyAU$029 Jul 19
Macquarie Investment Management Limited
EntityCompany
Shares157,615
Max PriceAU$0.11
BuyAU$313,60529 Jul 19
Kinetic Investment Partners Limited
EntityCompany
Shares4,100,000
Max PriceAU$0.076
BuyAU$2,11325 Jul 19
Judith Downes
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares27,534
Max PriceAU$0.077
SellAU$177,57208 Jul 19
UniSuper Limited
EntityCompany
Shares2,190,884
Max PriceAU$0.084
SellAU$12,89605 Jul 19
Macquarie Investment Management Limited
EntityCompany
Shares162,134
Max PriceAU$0.084
BuyAU$4,30505 Jul 19
Macquarie Investment Management Limited
EntityCompany
Shares48,595
Max PriceAU$0.091
SellAU$503,25302 Jul 19
UniSuper Limited
EntityCompany
Shares5,959,773
Max PriceAU$0.084
BuyAU$2,125,11328 Jun 19
UniSuper Limited
EntityCompany
Shares8,150,657
Max PriceAU$0.26
SellAU$2,125,11328 Jun 19
UniSuper Limited
EntityCompany
Shares8,150,657
Max PriceAU$0.26
BuyAU$844,56228 Jun 19
UniSuper Limited
EntityCompany
Shares7,432,487
Max PriceAU$0.18
SellAU$191,79326 Jun 19
Macquarie Investment Management Limited
EntityCompany
Shares1,458,338
Max PriceAU$0.13
BuyAU$229,53726 Jun 19
Macquarie Investment Management Limited
EntityCompany
Shares1,745,328
Max PriceAU$0.13
BuyAU$425,54920 Jun 19
Kinetic Investment Partners Limited
EntityCompany
Shares4,656,564
Max PriceAU$0.091
SellAU$1,551,65213 Jun 19
Kinetic Investment Partners Limited
EntityCompany
Shares7,184,073
Max PriceAU$0.22
BuyAU$1,719,84613 Jun 19
Kinetic Investment Partners Limited
EntityCompany
Shares8,239,770
Max PriceAU$0.21
SellAU$27,88127 May 19
Macquarie Investment Management Limited
EntityCompany
Shares202,708
Max PriceAU$0.14
BuyAU$5,86427 May 19
Macquarie Investment Management Limited
EntityCompany
Shares42,635
Max PriceAU$0.14
BuyAU$38,61224 Mar 19
Gary Goetzke
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares242,000
Max PriceAU$0.16
BuyAU$14,04124 Mar 19
Amit Patel
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares88,000
Max PriceAU$0.16
SellAU$022 Mar 19
Macquarie Investment Management Limited
EntityCompany
Shares3,807,407
Max PriceAU$0.35
BuyAU$022 Mar 19
Macquarie Investment Management Limited
EntityCompany
Shares5,444,050
Max PriceAU$0.37
SellAU$636,96719 Mar 19
FIL Limited
EntityCompany
Shares3,888,315
Max PriceAU$0.18
BuyAU$1,66412 Mar 19
Donald Williams
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares10,000
Max PriceAU$0.17
BuyAU$4,14811 Mar 19
Scott Ward
EntityIndividual
Role
Chairman of the Board
Non-Executive Chairman
Shares25,000
Max PriceAU$0.17
BuyAU$1,69208 Mar 19
Donald Williams
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares10,000
Max PriceAU$0.17
BuyAU$14,05106 Mar 19
Donald Williams
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares80,000
Max PriceAU$0.18
SellAU$693,67711 Feb 19
Starfish Ventures Pty Ltd
EntityCompany
Shares3,677,775
Max PriceAU$0.38
SellAU$670,28206 Feb 19
FIL Limited
EntityCompany
Shares3,875,449
Max PriceAU$0.17
BuyAU$143,13305 Feb 19
UniSuper Limited
EntityCompany
Shares843,555
Max PriceAU$0.18
SellAU$006 Jan 19
FIL Limited
EntityCompany
Shares4,347,426
Max PriceAU$0.59
BuyAU$006 Jan 19
FIL Limited
EntityCompany
Shares1,909,186
Max PriceAU$0.66

Ownership Breakdown


Management Team

  • Dave Adams

    Senior Vice President of Operations & Strategic Planning

    • Tenure: 0.7yrs
    • Compensation: AU$751.78k
  • Frank Vicini

    Chief Medical Officer

    • Tenure: 5yrs
  • Leanne Ralph

    Company Secretary

    • Tenure: 4.7yrs
  • Dennis Schlaht

    Senior Vice President of R&D and Technology

    • Tenure: 0yrs
    • Compensation: AU$884.15k
  • Cath Kingsford

    Senior Vice President of Medical Affairs

    • Tenure: 0yrs
    • Compensation: AU$795.44k
  • Nancy Deisinger

    Vice President of Human Resources

    • Tenure: 0.7yrs
  • Rick Carreon

    MD, CEO

    • Tenure: 7.2yrs
    • Compensation: AU$2.50m
  • Morten Vigeland

    Chief Financial Officer

    • Tenure: 6yrs
    • Compensation: AU$1.05m
  • Shashi Tripathi

    Chief Technology Officer

    • Tenure: 1.7yrs
    • Compensation: AU$1.13m

Board Members

  • Scott Ward (59yo)

    Non-Executive Chairman

    • Tenure: 1.8yrs
    • Compensation: AU$160.18k
  • Bob Graham

    Non-Executive Director

    • Tenure: 1.8yrs
    • Compensation: AU$73.91k
  • Don Williams (60yo)

    Non-Executive Director

    • Tenure: 2.5yrs
    • Compensation: AU$114.94k
  • Gary Goetzke

    Non-Executive Director

    • Tenure: 3.1yrs
    • Compensation: AU$94.04k
  • Judith Downes (65yo)

    Non-Executive Director

    • Tenure: 2.4yrs
    • Compensation: AU$82.13k
  • Rick Carreon

    MD, CEO

    • Tenure: 7.2yrs
    • Compensation: AU$2.50m
  • Amit Patel

    Non-Executive Director

    • Tenure: 2.5yrs
    • Compensation: AU$94.04k

Company Information

ImpediMed Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ImpediMed Limited
  • Ticker: IPDQ.F
  • Exchange: OTCPK
  • Founded: 1999
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$88.770m
  • Listing Market Cap: AU$60.102m
  • Shares outstanding: 507.26m
  • Website: https://www.impedimed.com

Number of Employees


Location

  • ImpediMed Limited
  • 50 Parker Court
  • Unit 1
  • Pinkenba
  • Queensland
  • 4008
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IPDASX (Australian Securities Exchange)YesOrdinary SharesAUAUDOct 2007
IPDQ.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDOct 2007
IPDCHIA (Chi-X Australia)YesOrdinary SharesAUAUDOct 2007
39IDB (Deutsche Boerse AG)YesOrdinary SharesDEEUROct 2007

Biography

ImpediMed Limited, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy devices and software services in Australia, North America, and internationally. It offers SOZO ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 00:14
End of Day Share Price2019/09/16 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.